This bill requires emergency medical services (EMS) providers in New Jersey - who administer opioid antidotes or treat drug overdose victims - to share specific information about the patient with the Department of Law and Public Safety (DLPS). The information, determined by the Attorney General, will be used to connect overdose survivors with harm reduction strategies and recovery resources, aiming to reduce immediate health risks. EMS providers include ambulance services, mobile medical units, and first aid squads. The Attorney General, with health officials, must later create rules to implement this requirement.
This bill requires New Jersey colleges to keep naloxone nasal spray in secure, accessible locations across campus residence halls for opioid overdose emergencies. It permits licensed medical staff (like nurses or doctors) and trained resident assistants to administer the medication during suspected overdoses, based on their good-faith belief. Institutions must develop policies designating a medical supervisor, requiring staff training on proper administration and overdose prevention, and mandating hospital transport after naloxone use - even if symptoms improve. The law also provides liability protection for good-faith actions by medical staff, resident assistants, or pharmacists following the bill's guidelines.
This bill (A 2648) requires involuntary commitment to mental health treatment for adults who have been administered an opioid antidote (like naloxone) for an apparent opioid overdose and are unwilling to accept voluntary treatment. It directly affects individuals experiencing opioid overdoses who receive emergency antidote treatment but refuse further care. The key provision amends the definition of "dangerous to self" to automatically include anyone who received an opioid antidote for overdose, eliminating the need for separate evaluation of risk in these cases. This changes the criteria for initiating involuntary commitment under New Jersey's mental health laws. The bill is currently pending in the Assembly Aging and Human Services Committee.
SCR 81 is a New Jersey concurrent resolution requesting the U.S. President and Congress to amend federal Medicaid rules to permit federal funding for substance use disorder treatment programs currently excluded under the "IMD exclusion." This exclusion prevents Medicaid reimbursement for inpatient and outpatient treatment in facilities classified as Institutions for Mental Diseases (IMDs), forcing states to cover full costs. The resolution seeks to repeal or modify this exclusion - allowing states like New Jersey to use federal Medicaid funds for these programs - thereby reducing state financial burdens and expanding access to treatment for individuals with substance use disorders.
This bill exempts from motor vehicle registration fees certain vehicles owned by local senior nutrition programs (specifically Meals on Wheels America members) and nonprofit organizations providing social services in New Jersey, such as addiction support or mental health services. The exemption applies to vehicles not used for pleasure or hire, requiring them to still be registered with standard or special number plates valid for up to 26 months. Owners may transfer the special registration to a new vehicle by applying to the chief administrator, maintaining compliance without fee payments.
New Jersey bill A 1775 requires health insurers (including hospital, medical, and health service corporations) to cover counseling and behavioral therapies for anyone receiving medication-assisted treatment (MAT) for opioid addiction. The bill mandates that this coverage be provided under the same terms and conditions as other medical treatments, prohibiting stricter limits on mental health/substance use disorder benefits compared to general medical care. It directly affects insured individuals seeking treatment for substance use disorders and requires insurers to comply with federal mental health parity standards. The law would apply to all health insurance contracts issued or renewed in New Jersey after its effective date.
New Jersey's A 2434 establishes a 26-member Behavioral Health Services Task Force within the Department of Human Services. The task force will study mental health and substance use disorder services county by county, identify gaps in care for children, adults, and emergency access, and make recommendations to improve service coordination, funding use, and program expansion. It must report findings and specific actionable steps to the Governor and Legislature within 18 months of the bill's effective date, after which the task force will dissolve. This bill directly affects all New Jersey residents seeking behavioral health services by initiating a state-level review process to address system weaknesses.
This bill requires New Jersey counties to appoint a pretrial release coordinator for defendants charged with serious offenses (indictable or disorderly persons) who are released before trial. The coordinator evaluates each defendant's needs and voluntarily connects them to services like substance abuse treatment, food assistance (SNAP), Medicaid, housing aid, job training (Work First NJ), and insurance applications. Counties must track which defendants access these services, along with demographic data and any subsequent arrests, and submit annual reports to the Governor and Legislature. The bill directly affects defendants on pretrial release and aims to improve access to supportive services during their court process.
This New Jersey bill requires general acute care hospitals to include fentanyl testing in urine drug screenings used to diagnose patient conditions. It directly affects hospitals conducting such screenings, mandating they test for fentanyl - a highly potent synthetic opioid often mixed with other drugs like cocaine or heroin, contributing to overdose deaths. The key provision adds fentanyl to standard screening panels, which currently test for substances like cocaine and other opioids but not fentanyl. The law takes effect immediately but expires on January 1, 2028.
New Jersey's bill A 2378 establishes a three-year Remote Methadone Dosing Pilot Program to test whether telehealth can improve opioid treatment. It selects one opioid treatment program each in Atlantic City, Camden, and Paterson to offer remote methadone dosing via approved telehealth technology, allowing eligible patients to receive take-home doses with remote monitoring when clinically appropriate. Participating programs must report annually on patient outcomes (like treatment compliance and retention) and cost savings (such as reduced transportation costs), with the state requiring a final report within four years to evaluate expansion potential. The bill appropriates $225,000 total ($75,000 per program) to fund the pilot and support participating opioid treatment programs.
